Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Role of ATP-binding cassette transporters in cancer initiation and progression.

Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E.

Semin Cancer Biol. 2019 Aug 11. pii: S1044-579X(19)30228-7. doi: 10.1016/j.semcancer.2019.08.006. [Epub ahead of print] Review.

PMID:
31412294
2.

Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.

Dei S, Braconi L, Trezza A, Menicatti M, Contino M, Coronnello M, Chiaramonte N, Manetti D, Perrone MG, Romanelli MN, Udomtanakunchai C, Colabufo NA, Bartolucci G, Spiga O, Salerno M, Teodori E.

Eur J Med Chem. 2019 Jun 15;172:71-94. doi: 10.1016/j.ejmech.2019.03.054. Epub 2019 Mar 27.

PMID:
30947123
3.

Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.

Dei S, Coronnello M, Bartolucci G, Manetti D, Romanelli MN, Udomtanakunchai C, Salerno M, Teodori E.

Eur J Med Chem. 2018 Mar 10;147:7-20. doi: 10.1016/j.ejmech.2018.01.092. Epub 2018 Feb 5.

PMID:
29421572
4.

Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR).

Dei S, Romanelli MN, Manetti D, Chiaramonte N, Coronnello M, Salerno M, Teodori E.

Bioorg Med Chem. 2018 Jan 1;26(1):50-64. doi: 10.1016/j.bmc.2017.11.016. Epub 2017 Nov 10.

PMID:
29162309
5.

N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.

Teodori E, Dei S, Coronnello M, Floriddia E, Bartolucci G, Manetti D, Romanelli MN, Santo Domingo Porqueras D, Salerno M.

Eur J Med Chem. 2017 Feb 15;127:586-598. doi: 10.1016/j.ejmech.2017.01.019. Epub 2017 Jan 13.

PMID:
28113128
6.

Development and characterization of an in vitro model of colorectal adenocarcinoma with MDR phenotype.

Cinci L, Luceri C, Bigagli E, Carboni I, Paccosi S, Parenti A, Guasti D, Coronnello M.

Cancer Med. 2016 Jun;5(6):1279-91. doi: 10.1002/cam4.694. Epub 2016 Mar 25.

7.

New Dendrimer-Based Nanoparticles Enhance Curcumin Solubility.

Falconieri MC, Adamo M, Monasterolo C, Bergonzi MC, Coronnello M, Bilia AR.

Planta Med. 2017 Mar;83(5):420-425. doi: 10.1055/s-0042-103161. Epub 2016 Mar 22.

PMID:
27002394
8.

Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells.

Leto I, Coronnello M, Righeschi C, Bergonzi MC, Mini E, Bilia AR.

ChemMedChem. 2016 Aug 19;11(16):1745-51. doi: 10.1002/cmdc.201500586. Epub 2016 Mar 21.

PMID:
26999297
9.

Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.

Dei S, Coronnello M, Floriddia E, Bartolucci G, Bellucci C, Guandalini L, Manetti D, Romanelli MN, Salerno M, Bello I, Mini E, Teodori E.

Eur J Med Chem. 2014 Nov 24;87:398-412. doi: 10.1016/j.ejmech.2014.09.084. Epub 2014 Sep 30.

PMID:
25282263
10.

Strategy to provide a useful solution to effective delivery of dihydroartemisinin: development, characterization and in vitro studies of liposomal formulations.

Righeschi C, Coronnello M, Mastrantoni A, Isacchi B, Bergonzi MC, Mini E, Bilia AR.

Colloids Surf B Biointerfaces. 2014 Apr 1;116:121-7. doi: 10.1016/j.colsurfb.2013.12.019. Epub 2014 Jan 6.

PMID:
24462780
11.

New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).

Orlandi F, Coronnello M, Bellucci C, Dei S, Guandalini L, Manetti D, Martelli C, Romanelli MN, Scapecchi S, Salerno M, Menif H, Bello I, Mini E, Teodori E.

Bioorg Med Chem. 2013 Jan 15;21(2):456-65. doi: 10.1016/j.bmc.2012.11.019. Epub 2012 Nov 24.

PMID:
23245571
12.

Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.

Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, Scapecchi S, Novella Romanelli M, Salerno M, Mini E, Teodori E.

J Med Chem. 2010 Feb 25;53(4):1755-62. doi: 10.1021/jm9016174.

PMID:
20104851
13.

N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors.

Martelli C, Alderighi D, Coronnello M, Dei S, Frosini M, Le Bozec B, Manetti D, Neri A, Romanelli MN, Salerno M, Scapecchi S, Mini E, Sgaragli G, Teodori E.

J Med Chem. 2009 Feb 12;52(3):807-17. doi: 10.1021/jm8012745.

PMID:
19140665
14.

Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.

Ciciani G, Coronnello M, Guerrini G, Selleri S, Cantore M, Failli P, Mini E, Costanzo A.

Bioorg Med Chem. 2008 Nov 1;16(21):9409-19. doi: 10.1016/j.bmc.2008.09.055. Epub 2008 Sep 26.

PMID:
18845441
15.

Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands.

Casini A, Cinellu MA, Minghetti G, Gabbiani C, Coronnello M, Mini E, Messori L.

J Med Chem. 2006 Sep 7;49(18):5524-31.

PMID:
16942025
16.

Mechanisms of cytotoxicity of selected organogold(III) compounds.

Coronnello M, Mini E, Caciagli B, Cinellu MA, Bindoli A, Gabbiani C, Messori L.

J Med Chem. 2005 Oct 20;48(21):6761-5.

PMID:
16220992
17.

Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents.

Coronnello M, Ciciani G, Mini E, Guerrini G, Caciagli B, Selleri S, Costanzo A, Mazzei T.

Anticancer Drugs. 2005 Jul;16(6):645-51.

PMID:
15930893
18.

Pirenoxine prevents oxidative effects of argon fluoride excimer laser irradiation in rabbit corneas: biochemical, histological and cytofluorimetric evaluations.

Cantore M, Siano S, Coronnello M, Mazzetti L, Franchi-Micheli S, Boldrini E, Ciuffi M, Failli P.

J Photochem Photobiol B. 2005 Jan 14;78(1):35-42.

PMID:
15629247
19.

Solution chemistry and cytotoxic properties of novel organogold(III) compounds.

Messori L, Marcon G, Cinellu MA, Coronnello M, Mini E, Gabbiani C, Orioli P.

Bioorg Med Chem. 2004 Dec 1;12(23):6039-43.

PMID:
15519149
20.

Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells.

Prignano F, Coronnello M, Pimpinelli N, Cappugi P, Mini E, Giannotti B.

Cancer Lett. 2002 Dec 5;186(2):183-92.

PMID:
12213288
21.

Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.

Marcon G, Carotti S, Coronnello M, Messori L, Mini E, Orioli P, Mazzei T, Cinellu MA, Minghetti G.

J Med Chem. 2002 Apr 11;45(8):1672-7.

PMID:
11931621
22.

Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity.

Coronnello M, Marcon G, Carotti S, Caciagli B, Mini E, Mazzei T, Orioli P, Messori L.

Oncol Res. 2000;12(9-10):361-70.

PMID:
11697815
23.

Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro.

Noci I, Coronnello M, Borri P, Borrani E, Giachi M, Chieffi O, Marchionni M, Paglierani M, Buccoliero AM, Cherubini A, Arcangeli A, Mini E, Taddei G.

Cancer Lett. 2000 Mar 13;150(1):71-8.

PMID:
10755389
24.

Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.

Morganti M, Coronnello M, Caciagli B, Biondi C, Quattrone A, Capaccioli S, Mazzei T, Mini E.

Anticancer Drugs. 2000 Apr;11(4):285-94.

PMID:
10898545
25.

Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.

Borri P, Coronnello M, Noci I, Pesciullesi A, Peri A, Caligiani R, Maggi M, Torricelli F, Scarselli G, Chieffi O, Mazzei T, Mini E.

Gynecol Oncol. 1998 Dec;71(3):396-403.

PMID:
9887238
26.

Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat.

Cini G, Coronnello M, Mini E, Neri B.

Cancer Lett. 1998 Mar 13;125(1-2):51-9.

PMID:
9566696
27.

A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells.

Arcangeli A, Bianchi L, Becchetti A, Faravelli L, Coronnello M, Mini E, Olivotto M, Wanke E.

J Physiol. 1995 Dec 1;489 ( Pt 2):455-71.

28.

Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance.

Quattrone A, Papucci L, Morganti M, Coronnello M, Mini E, Mazzei T, Colonna FP, Garbesi A, Capaccioli S.

Oncol Res. 1994;6(7):311-20.

PMID:
7865906
29.

In vitro effects of brodimoprim on human polymorphonuclear leukocyte functions. Preliminary results.

Mini E, Novelli A, Coronnello M, Fallani S, Pesciullesi A, Periti P.

J Chemother. 1993 Dec;5(6):499-501.

PMID:
8195845
30.

Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation.

Mini E, Stanyon R, Coronnello M, Gerli A, Mazzei T, Periti P.

Tumori. 1991 Apr 30;77(2):95-9.

PMID:
2048234
31.

Biochemical modulation of fluoropyrimidines by antifolates and folates in an in vitro model of human leukemia.

Mini E, Coronnello M, Carotti S, Gerli A, Pesciullesi A, Moroson BA, Mazzei T, Periti P, Bertino JR.

J Chemother. 1990 Feb;2 Suppl 1:17-27. Review.

PMID:
2142214
32.

Induction of differentiation of HL-60 cells along the monocytic pathway by 5-methyltetrahydrofolate.

Bernabei PA, Mini E, Gattei V, Agostino FC, Bezzini R, Saccardi R, Santini V, Coronnello M, Mazzei T, Rossi Ferrini P.

J Chemother. 1989 Dec;1(6):359-64.

PMID:
2614501
33.

Impaired methotrexate polyglutamylation in a human leukemia cell line resistant to short-term, high-dose methotrexate.

Mini E, Pizzorno G, Coronnello M, McGuire JJ, Mazzei T, Periti P, Bertino JR.

Pharmacol Res Commun. 1988 May;20(5):445-6. No abstract available.

PMID:
2458604
34.

Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.

Pizzorno G, Mini E, Coronnello M, McGuire JJ, Moroson BA, Cashmore AR, Dreyer RN, Lin JT, Mazzei T, Periti P, et al.

Cancer Res. 1988 Apr 15;48(8):2149-55.

35.

Effects of 5-methyltetrahydrofolate on the activity of fluoropyrimidines against human leukemia (CCRF-CEM) cells.

Mini E, Mazzei T, Coronnello M, Criscuoli L, Gualtieri M, Periti P, Bertino JR.

Biochem Pharmacol. 1987 Sep 15;36(18):2905-11.

PMID:
2958010
36.

Enhancement of fluoropyrimidine cytotoxicity by 5-methyltetrahydrofolate in a human leukemia cell line, CCRF-CEM.

Mini E, Mazzei T, Coronnello M, Criscuoli L, Gualtieri M, Periti P.

Chemioterapia. 1985 Dec;4(6):454-9.

PMID:
2937563
37.

Alkaline elution of DNA as a method for assessing genotoxic effects of drugs: its application to a series of antiviral compounds.

Coronnello M, Caderni G, Dolara P.

Methods Find Exp Clin Pharmacol. 1985 Jan;7(1):29-34.

PMID:
3887068
38.

Modulation of fluoropyrimidine cytotoxicity by methotrexate or 5-methyltetrahydrofolate in human leukemia cells in vitro.

Mini E, Mazzei T, Coronnello M, Criscuoli L, Gualtieri M, Periti P.

Chemioterapia. 1984 Dec;3(6):343-9.

PMID:
6241507
39.

Clinical chemotherapeutic evaluation of fosfomycin plus amoxicillin (co-fosfolactamine): a prospective double-blind clinical trial.

Novelli A, Rizzo M, Buzzoni P, Coronnello M, Alunno Pergentini S, Giganti E, Periti P.

Chemioterapia. 1984 Oct;3(5):281-5.

PMID:
6398125

Supplemental Content

Loading ...
Support Center